Clinical Trial Update: Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating nab-sirolimus in combination with FOLFOX and bevacizumab as first-line therapy for advanced or metastatic colorectal cancer has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOX
• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Aadi Bioscience, Inc. | Conditions: Colorectal Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-02